(UML-491) is a prescription drug used for prophylaxis of migraine headaches
and is sold under the brand names Sansert and Deseril in 2mg dosages. Methysergide was approved by the FDA
in 1962. Its molecular structure is closely related to that of LSD
. It is a receptor antagonist
for the 5-HT receptor 2C
. It also is a 5-HT1A receptor antagonist.
It is known to have partial agonists effects on 5-HT receptors as well.
Methysergide is one of the most effective medications for the prevention of migraine, but not for the treatment of an acute attack. It has a known side effect, retroperitoneal fibrosis, which is severe, although uncommon. In addition, there is an increased risk of left-sided cardiac valve dysfunction.
Novartis withdrew it from the U.S. market after taking over Sandoz, but currently lists it as a product.
Like LSD, methysergide also produces psychedelic
and hallucinogenic effects above a dosage of about 4mg. Full effects are felt with dosages of 8-20mg.
About 4 mg is equal to 25mcg of LSD.